Testing palbociclib alone and with pembrolizumab for cancer that has spread to the brain or spinal cord
Official title: Palbociclib and Pembrolizumab In Central Nervous System Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing two drugs, one by itself and the two together, in people whose cancer has spread to the brain or spinal cord and has come back.
Read our full plain-language summary
What the trial team says
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: * Palbociclib alone (Cohort 1) * The combination of palbociclib and pembrolizumab (Cohort 2) Pfizer and Merck, pharmaceutical companies, are supporting this research study by providing the study drugs as well as funding for research activities.
Key facts
- Registry number
- NCT02896335
- Stage of testing
- Phase 2
- Conditions studied
- Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
Where it is running
This trial lists 2 sites.
-
Massachusetts
- Massachusetts General Hospital (Boston)
- Dana Farber Cancer Institute (Boston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.